Search

Displaying results 8911 - 8920 of 10000 in total
  1. Drug

    5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole

    go.drugbank.com/drugs/DB08724
    Experimental

    This medication is known to target genome polyprotein. … 5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers.

  2. Drug

    Probiorinse

    go.drugbank.com/drugs/DB15870
    Experimental

    [L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193] … Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.

  3. Drug

    Vabametkib

    go.drugbank.com/drugs/DB21629
    Investigational

    Vabametkib is a small molecule drug. … Vabametkib is under investigation in clinical trial NCT05541822 (To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET

  4. Drug

    Prinaberel

    go.drugbank.com/drugs/DB06832
    Investigational

    Prinaberel is an estrogen receptor beta agonist.

  5. Drug

    Dapiclermin

    go.drugbank.com/drugs/DB17979
    Experimental

    Dapiclermin is a recombinant ciliary neurotrophic factor.

  6. Drug

    M1-c6v1

    go.drugbank.com/drugs/DB18596
    Investigational

    M1-c6v1 is a recombinant oncolytic virus.

  7. Drug

    Netoglitazone

    go.drugbank.com/drugs/DB09199
    Experimental

    Netoglitazone (MCC-555) is a hypoglycemic agent.

  8. Drug

    SYNB1353

    go.drugbank.com/drugs/DB17666
    Investigational

    SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … [A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria.

  9. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    NTLA-2002 is a lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9. … It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]

  10. Drug

    mRNA-3927

    go.drugbank.com/drugs/DB17669
    Investigational

    Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.[L45998] … mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid